Brief: Camurus Says NDA Resubmission For CAM2029 In Acromegaly Accepted For Review By FDA
17/07/2026 06:10
BRIEF-Camurus Says NDA Resubmission For CAM2029 In Acromegaly Accepted For Review By FDA July 17 (Reuters) - Camurus AB CAMX.ST:
NDA RESUBMISSION FOR CAM2029 IN ACROMEGALY ACCEPTED FOR REVIEW BY THE US FDA
Source text: ID:nWkr2HVs1
Further company coverage: CAMX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Camurus AB
See all newsBrief: Camurus Receives Approval In Canada For Oczyesa XR
Brief: Executive Sells About £279,000 Of Camurus Shares
Jefferies cuts Ipsen to 'underperform' on Somatuline competition risk
Brief: Camurus Says NDA Resubmission For CAM2029 In Acromegaly Accepted For Review By FDA
Camurus shares rise after Q2 revenue, operating profit beat